PAIN MANAGEMENT DRUGS MARKET ANALYSIS
Global Pain Management Drugs Market: Key Developments
In April 2022, Eli Lilly and Company, a pharmaceutical company, Eli Lilly and Company passed phase II trial for LY3556050, a small molecule Somatostatin receptor type 4 (SSTR4 agonist). LY3556050, is designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain. Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene.
In April 2022, Eli Lilly and Company, a pharmaceutical company, passed phase II trial for LY3526318, an oral, highly selective, small molecule antagonist of transient receptor potential ankyrin 1 (TRPA1). LY3526318 is a calcium-permeable nonselective cation channel expressed in pain sensing peripheral nerves. It is being developed as a non-opioid treatment for chronic pain conditions.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
